For fourteen years I have had the privilege of supporting Hertfordshire’s Local Enterprise Partnership (LEP), working alongside outstanding business leaders, local authorities, universities, colleges and government departments to drive economic growth across one of the UK’s most successful counties. Today, as Chair of Hertfordshire Futures, that work continues through its integration into Hertfordshire County Council. The name has changed, but the mission remains the same: creating opportunity, supporting business and delivering prosperity for our communities.

That is why the decision to abolish Local Enterprise Partnerships remains so difficult to understand.

LEPs were never designed to be political organisations. They were created to provide a direct connection between government and the businesses that create wealth, employment and innovation. They brought together people who understood local economies, local opportunities and local challenges far better than officials sitting hundreds of miles away in Whitehall.

Across Hertfordshire, that partnership model delivered exceptional results. Businesses, education providers and public sector organisations worked together to improve skills, attract investment, support innovation, strengthen infrastructure and help thousands of businesses grow. The county became one of the UK’s leading economic performers because decisions were increasingly shaped by those with first-hand knowledge of the local economy.

The principle was simple but powerful: those closest to the economy are usually best placed to identify what it needs.

Britain remains one of the most centralised countries in the developed world, with far too many important decisions controlled from Westminster. Successive governments have recognised this problem and spoken passionately about devolution, yet meaningful power has often remained firmly held at the centre.

The challenge has never been a shortage of capable local leadership. It has been the tendency of national governments to continually reorganise institutions before they have been given sufficient time to mature. Regional Development Agencies were abolished. LEPs followed. New structures emerged. Valuable expertise was dispersed, relationships had to be rebuilt, and institutional knowledge was repeatedly lost. Businesses value certainty, consistency and long-term thinking. Constant restructuring achieves the opposite.

Thankfully, Hertfordshire has largely avoided losing that expertise. Through Hertfordshire Futures, we have retained the partnership between business and local government that made the LEP successful in the first place. Business remains at the heart of economic decision-making while benefiting from closer integration with the County Council and its wider public services.

This evolution demonstrates that successful organisations should be strengthened rather than discarded.

If Britain is serious about improving productivity, attracting investment and creating sustainable growth, local leadership must be trusted with greater responsibility. National government should establish the framework and provide resources, but local economic priorities should be shaped by those who understand their places best.

The lesson from Hertfordshire is clear. Long-term partnerships between business, education and government deliver results. They build confidence, attract investment and create lasting prosperity. The objective should never be to continually reinvent the machinery of economic development, but to give successful local partnerships the stability, powers and confidence to deliver over decades rather than political cycles.

Economic growth is not created in Whitehall. It is created in our towns, cities, businesses and communities. The role of government should be to empower those places—not repeatedly reorganise them. Hopefully this will be where Andy Burnham MP PM places his support.

The United Kingdom rightly prides itself on being one of the world’s oldest democracies. Universal suffrage was not gifted lightly; it was earned over generations through sacrifice, reform and the belief that every citizen should have a voice in shaping the nation’s future.

Yet democracy is not standing still. Falling electoral turnout, declining trust in politics and increasing polarisation have left many questioning whether our electoral system still serves the country as well as it should. The proposals reportedly being considered by Andy Burnham’s advisers—including compulsory voting, a modest £10 fine for non-voters and a “None of the Above” option—deserve serious debate rather than instinctive rejection.

Australia demonstrates that compulsory voting can work. Since introducing it in 1924, turnout has consistently exceeded 90 per cent. Governments enjoy stronger mandates, extreme political movements struggle to dominate elections through motivated minorities alone, and parties are encouraged to speak to the whole electorate rather than simply mobilising their core supporters.

Britain should certainly learn from that experience.

Automatic voter registration expanded postal and early voting, stronger civic education in schools and a legally recognised “None of the Above” option would all modernise our democratic process while preserving individual freedom of political expression.

However, if voting becomes a civic duty, should civic responsibility extend further?

There is a legitimate debate over whether those who deliberately reject the social contract should continue to exercise every democratic right without restriction. Most convicted prisoners already lose the right to vote while serving custodial sentences, reflecting society’s judgement that serious criminal offending carries consequences beyond imprisonment.

Beyond that, reform becomes considerably more difficult.

Some argue that long-term welfare recipients who make no contribution through employment should also lose voting rights. While superficially attractive to some, such an approach would create profound problems. Many people receiving long-term benefits are disabled, caring for relatives, recovering from illness or simply unable to find suitable work. Citizenship has never been contingent on income, and governments make decisions that affect every citizen, regardless of their employment status.

A better question may be whether Britain should do more to encourage contribution rather than punish dependency.

Those capable of working could be offered stronger incentives and clearer expectations to participate in employment, training, volunteering or community service. Democracy flourishes when citizens feel they have both a stake in society and an opportunity to shape it.

Perhaps the most important lesson from Australia is not compulsory voting itself, but the principle that democracy is both a right and a responsibility.

Britain should seize this opportunity to modernise its electoral system. Compulsory participation, easier access to voting, automatic registration, civic education, secure voter identification and a “None of the Above” option could collectively strengthen public confidence. At the same time, government must pursue policies that encourage every citizen to contribute to society wherever they are able.

Democracy is strongest not when the greatest number simply cast a ballot, but when the greatest number have a genuine stake in the nation’s success. Rights and responsibilities should never be seen as competing ideals. They are the twin foundations upon which every enduring democracy is built.

GSK’s announcement of a £400 million investment in a new global research and development centre on the Cambridge Biomedical Campus is excellent news for the United Kingdom. It reinforces Cambridge’s position as one of the world’s foremost centres for biomedical research and underlines the confidence that major international companies continue to place in British science.

Yet the announcement also highlights a much bigger question. Are we recognising that life sciences are entering a new era, one in which the medicines of tomorrow will look fundamentally different from those that have transformed healthcare over the past century?

For generations, the pharmaceutical industry has been built upon the discovery, manufacture and distribution of medicines designed for millions of patients. Whether antibiotics, vaccines, cardiovascular drugs or cancer treatments, these medicines have saved countless lives and will continue to do so. They remain an essential foundation of modern healthcare.

Alongside this established model, however, a second revolution is rapidly emerging.

Cell and Gene Therapies are changing the very nature of medicine. Rather than treating symptoms or slowing disease progression, many of these therapies are designed to correct the underlying biological cause of disease. Increasingly, they are personalised for individual patients, using their own cells or precise genetic interventions to restore normal function.

This represents a profound shift in medical science. The focus is moving from mass-produced medicines towards precision treatments capable of tackling conditions once considered incurable.

This is where Stevenage occupies a unique position.

Over the past decade, Stevenage has quietly become one of the world’s leading centres for Cell and Gene Therapy development. The Cell and Gene Therapy Catapult, Stevenage Bioscience Catalyst and a growing cluster of pioneering biotechnology companies have created an internationally recognised ecosystem where research, clinical development, manufacturing and commercialisation exist side by side.

This capability is not in competition with Cambridge. It is its natural partner.

Cambridge excels in world-class scientific discovery, academic excellence and clinical research. Stevenage provides the expertise to translate many of those discoveries into advanced therapies that can be manufactured safely, efficiently and at commercial scale for patients across the world.

Together they create something few countries can match: a complete innovation pathway from laboratory discovery to patient treatment.

As Government continues to develop its Industrial Strategy and Life Sciences Vision, it should resist concentrating attention on a single location, however successful. Instead, it should champion a Cambridge–Stevenage innovation corridor that combines discovery science with advanced therapy development and manufacturing.

Britain already possesses the ingredients to become the global leader in next-generation medicine. Cambridge provides the ideas. Stevenage provides the pathway to delivering them to patients.

The future of healthcare will not be built by choosing between pharmaceuticals and personalised therapies. It will be built by recognising that both are essential—and by ensuring that Britain’s investment strategy reflects the complementary strengths of each.

If Cambridge discovers tomorrow’s breakthroughs, Stevenage can help turn them into tomorrow’s cures.

GSK’s decision to invest £400 million in a flagship research centre on the Cambridge Biomedical Campus confirms Britain’s position as one of the world’s leading centres for pharmaceutical research. Cambridge deserves that recognition. Its universities, hospitals and research institutes have helped shape modern medicine for generations.

Yet the announcement also exposes a far more important question. Is Britain investing as confidently in the future of medicine as it is in its past?

Traditional pharmaceutical research has transformed healthcare. Mass-produced medicines have eradicated diseases, prolonged life expectancy and improved the quality of life for billions of people. They will continue to play a vital role in treating chronic illness, infection and countless medical conditions.

However, medicine is undergoing a fundamental transition.

Many of tomorrow’s greatest breakthroughs will not come from developing another tablet or injectable medicine designed for millions of identical patients. They will come from therapies created specifically for one individual, using that person’s own cells or genetic material to eliminate diseases that conventional pharmaceuticals have never been able to cure.

This is not simply an evolution of pharmaceutical science. It is an entirely different application of medical science.

Cell and Gene Therapies do not merely manage disease; increasingly, they seek to correct or replace the underlying biological cause. Instead of slowing illness, they offer the prospect of long-term remission and, in some cases, genuine cures.

Stevenage has become one of the world’s leading centres for this revolution.

The Cell and Gene Therapy Catapult, Stevenage Bioscience Catalyst and an internationally respected community of biotechnology companies have created capabilities that few countries possess. Here, personalised therapies are being developed, manufactured and commercialised at scale.

Perhaps the clearest example is Autolus. Established in Stevenage, the company has pioneered CAR-T cell therapies that re-engineer a patient’s own immune cells to attack certain blood cancers. For patients with forms of leukaemia who had exhausted conventional treatment options, this technology has demonstrated that diseases once regarded as incurable can, in some cases, be driven into remission through personalised medicine rather than conventional pharmaceutical intervention.

That represents more than scientific progress. It represents a change in philosophy.

Britain should not view Cambridge and Stevenage as competitors. Cambridge remains one of the world’s great centres of biomedical discovery. Stevenage is becoming one of the places where medicine itself is being redefined.

If our national strategy focuses primarily on traditional pharmaceutical discovery while underestimating advanced therapies, we risk investing disproportionately in yesterday’s industrial model while other nations seize leadership in tomorrow’s.

The next century of medicine will not be measured simply by how many new drugs we discover. It will be measured by how many diseases we no longer need drugs to manage because personalised therapies have learned how to cure them.

That is the opportunity Britain cannot afford to overlook.

Cambridge will continue to discover tomorrow’s medicines. Hertfordshire could help deliver tomorrow’s cures. Britain’s Life Sciences Strategy must recognise the difference.

GSK’s announcement of a £400 million investment in a new global Research and Development centre on the Cambridge Biomedical Campus is welcome news. It reinforces Britain’s standing as a world leader in pharmaceutical research and confirms Cambridge’s position as one of the most important centres of biomedical discovery anywhere in the world.

The investment will bring together more than 1,000 scientists within one of Europe’s largest biomedical campuses, surrounded by internationally renowned universities, teaching hospitals, biotechnology companies and artificial intelligence specialists. Few locations can rival Cambridge’s ability to generate scientific discovery.

Yet the announcement also highlights a strategic question that Britain cannot afford to ignore.

Are we investing as confidently in the future of medicine as we are in its past?

For more than a century, pharmaceutical companies have transformed healthcare through medicines manufactured for millions of patients. Antibiotics, vaccines, cardiovascular drugs and cancer treatments have extended life expectancy across the globe and remain fundamental to modern medicine.

However, medicine is entering a fundamentally different era.

Increasingly, the greatest breakthroughs will not come from developing another medicine designed for the masses. They will come from therapies created for individual patients using their own cells or genetic material to correct the underlying cause of disease itself.

This is not simply the next chapter of pharmaceutical development. It represents a different application of medical science.

Traditional pharmaceuticals largely manage disease, control symptoms or slow progression. Cell and Gene Therapies increasingly seek to repair, replace or reprogramme the body’s own biological systems, offering the possibility of long-term remission and, in some cases, genuine cures for conditions that conventional medicines have never been able to overcome.

One only has to look at Autolus, established in Stevenage, whose pioneering CAR-T cell therapies harness a patient’s own immune cells to fight certain forms of leukaemia. For patients who had exhausted conventional treatment options, this technology has demonstrated that personalised medicine can achieve outcomes that traditional pharmaceuticals alone could not.

This is precisely why Hertfordshire deserves greater national recognition.

Over the past decade, Stevenage has quietly become one of the world’s leading centres for Cell and Gene Therapy. The Cell and Gene Therapy Catapult, Stevenage Bioscience Catalyst and an expanding community of advanced biotechnology companies have created one of the most sophisticated ecosystems for developing, manufacturing and commercialising personalised therapies anywhere in Europe.

Confidence in Hertfordshire’s future extends beyond Stevenage. The University of Hertfordshire is investing £103 million in a new Health Innovation Campus, opening in 2028, creating world-class facilities for educating healthcare professionals, advancing medical research and strengthening collaboration between universities, the NHS and industry.

These are not isolated investments.

Together they demonstrate that Hertfordshire is becoming a nationally significant centre where education, research, advanced manufacturing, clinical practice and commercial innovation converge to shape the future of healthcare.

This should not become a debate about Cambridge versus Hertfordshire.

Cambridge excels in scientific discovery. Hertfordshire is increasingly demonstrating how those discoveries can be translated into advanced therapies, commercial manufacturing and life-changing patient treatments.

Together they create a complete innovation pathway—from laboratory discovery to personalised cure.

Government’s forthcoming Life Sciences Strategy should therefore look beyond individual locations and recognise the emergence of a Cambridge–Hertfordshire Life Sciences Corridor. Such a partnership would combine one of the world’s greatest centres of scientific discovery with one of the world’s most exciting centres for advanced therapies and healthcare innovation.

Britain’s ambition should not simply be to discover more medicines.

It should be to lead the world in developing treatments that eliminate disease altogether.

If Cambridge helps discover tomorrow’s science, Hertfordshire is increasingly showing how Britain can transform that science into cures.

That is the future of medicine—and it is a future Britain must choose to lead.

Customer expectations have never been higher, and the tolerance for poor service has never been lower. As business owners, we’re seeing this shift unfold in real time: customers now expect instant, accurate, and personalised responses at any hour and across every channel. The pressure to deliver is considerable, and artificial intelligence has moved from being one option for meeting that pressure to becoming the baseline expectation.  For any leader who has not yet established a clear, strategic position on AI in customer service, the window for deliberation is closing rapidly.

The Evidence Is Clear: AI Is Becoming the Standard
The scale of AI adoption in customer service is significant, and its trajectory makes the trend impossible to ignore. The AI customer service market value reached $12 billion in 2024 but is projected to reach $47.8 billion by 2030, a compound annual growth rate of 25.8%. Growth of that magnitude does not occur without tangible business results driving it. Gartner projects that 80 % of customer service and support organisations will use Agentic Generative AI to improve customer service productivity and the overall customer experience.

The Return on Investment Justifies the Enthusiasm
According to International Data Corporation (IDC) early-adopter companies report an average return of $3.50 for every $1 invested in AI customer service, and leading organisations are achieving as much as 8x ROI. For any executive evaluating technology investments, figures of that order warrant serious attention.

Perhaps the most revealing indicator is what happens operationally once AI is deployed. With AI-powered support, first response times for customer enquiries have fallen from more than six hours to under four minutes, and in some cases resolution times have been reduced from over 30 hours to just 30 minutes. These are transformational improvements.

The Human-AI Partnership: A Strategic Advantage
One of the most persistent misconceptions encountered among business leaders is the belief that deploying AI in customer service means replacing their people. The data tells a more nuanced and far more encouraging story. The most competitive organisations are not choosing between humans and AI, they are combining the two strategically.

According to Zendesk’s 2025 CX Trends report, 79% of customer-service (“CS”) team members say that having an AI copilot improves their ability to deliver excellent service.  That shows a workforce more empowered by technology than threatened by it.  Generative AI is already improving efficiency through case summaries and email drafting, with innovative teams CS reporting an 80% reduction in the time required to produce a case summary and productivity gains of 10-20%.

ISG (Information Security Group) notes that, while AI delivers substantial efficiency gains, 75% of customers still prefer human agents for complex issues.  The most successful companies therefore use AI for speed with resolving low complexity cases, and rely on people for nuanced responses to escalated ones.   The AI permits focussed attention by team members where it is needed.

That hybrid model is the competitive advantage. Leaders who recognise this will build service operations that are both leaner and more empathetic than their purely human or purely automated counterparts.

From Reactive to Proactive: The New Service Paradigm
AI is not simply accelerating how quickly your team responds, it is fundamentally changing when and how you engage with customers. The shift from reactive ticket management to proactive, intelligence-driven service is one of the most significant strategic opportunities available to customer experience leaders today.

Zendesk’s 2025 research finds that 90% of leading CS departments expect AI and automation to soon resolve 8/10 customer issues without human intervention, and the pathway to that future is already being built. Reactive ticket queues are becoming the minimum standard, the current playbook is to anticipate issues and intervene early, guided by signals drawn from product telemetry, billing anomalies, and conversation trends.

AI-powered systems have produced a 31.5 percent increase in customer satisfaction scores and a 24.8 percent improvement in customer retention, clear gains in both experience and loyalty. For a business leader focused on lifetime customer value, those figures represent a direct line to revenue, not merely cost savings.

McKinsey’s State of AI 2025 reinforces this point, noting that organisations using AI to drive growth and innovation are more likely to report improved customer satisfaction, competitive differentiation, profitability, and revenue growth. The highest-performing organisations are not using AI beyond just reducing costs: they are using it to grow.

Where Implementations Go Wrong
Understanding the opportunity is only half the equation. As a leader, I would be doing you a disservice if I did not acknowledge where organisations stumble. Implementation quality is decisive. The principal risks are over-automation, poor integration, an incomplete knowledge base, the loss of the human touch, and data privacy concerns.  44% of organisations have learned through negative consequences — most often from rushing implementation without adequate planning.

While 88% of enterprise contact centres use AI in some capacity, <25% have fully integrated automation into their daily workflows, and that gap separates the businesses extracting real value from those still experimenting.  Implementation approach matters more than technology selection. The organisations achieving exceptional returns concentrate on narrow use cases, deep integration, and production-grade infrastructure – thoroughly tested before releasing to customers.

The lessons are clear:  Begin with a defined problem not a technology; Identify the interactions that are high in volume, low in complexity, and high in frustration for both your customers and your team and build from there.

Brexit remains one of the most contested political decisions in modern British history, yet the economic record since the 2016 referendum provides a credible defence of the decision to leave the European Union.

Average annual UK exports before the referendum stood at approximately $710 billion. In the decade following the vote, that figure rose to roughly $899 billion per year, despite the severe disruption caused by the COVID-19 pandemic. While critics often highlight individual trade frictions, the broader picture suggests that Britain retained its position as a major global trading nation outside the EU.

Before Brexit, approximately 46% of UK exports went to the European Union. In the years following Brexit, that proportion declined to around 41%, reflecting a diversification of British trade toward global markets beyond Europe. At the same time, total exports still increased overall in monetary value, particularly in services such as finance, technology, legal expertise, and consulting.

Imports also followed a similar pattern. Average annual UK imports rose from approximately $820 billion before Brexit to around $1.01 trillion afterward. Prior to Brexit, around 53–55% of imports came from the EU, whereas post-Brexit this reduced to approximately 48–50%. Although the EU remained Britain’s largest trading partner, the UK increasingly sourced goods and services from the United States, Asia, and emerging international markets.

Supporters of closer EU alignment, including Wes Streeting and Andy Burnham, have increasingly argued for rebuilding stronger institutional ties with Europe, while critics suspect Sir Keir Starmer’s government is gradually steering Britain back toward EU structures. Much of the political argument now centres on practical inconveniences such as passport queues, travel friction, and mobility restrictions. These concerns are genuine, but they are relatively minor when weighed against the constitutional issue that motivated many Brexit voters: democratic accountability and the right for the UK Parliament to control laws, borders, and trade policy independently.

Brexit has not been without shortcomings. Smaller exporters have faced additional bureaucracy, some industries experienced labour shortages, and trade with the EU became administratively more complex. However, opponents often overlook that the UK economy simultaneously expanded service exports, strengthened trade relationships beyond Europe, and demonstrated resilience during one of the most difficult global economic periods in generations.

The central Brexit argument was never simply about convenience. It was about sovereignty, national decision-making, and long-term flexibility. Measured against those objectives, and alongside the continued strength of UK exports and imports, there remains a strong case that leaving the European Union was the correct decision for Britain.